<DOC>
	<DOCNO>NCT01280305</DOCNO>
	<brief_summary>The objective study evaluate efficacy raloxifene compare placebo , add-on anti-psychotics treatment post menopausal patient schizophrenia .</brief_summary>
	<brief_title>Raloxifene Treatment Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>Epidemiological evidence show potentially protective role estrogen woman schizophrenia . The onset schizophrenia later woman men , generally less severe course menopause , many woman , reduction estrogen level appear trigger exacerbation illness ( Hafner 2003 ) . ERÎ± ( Estrogen receptor alpha ) expression know reduce schizophrenia ( Wong , Woon et al . 2010 ) . Raloxifene selective estrogen receptor modulator act estrogen antagonist breast tissue may agonistic action brain . Several study ( Kulkarni , Riedel et al . 2001 ; Chua , de Izquierdo et al . 2005 ; Kulkarni , Gurvich et al . 2010 ) indicate treatment estrogen raloxifene improve symptom female schizophrenia , recently show improvement PANSS score post menopausal woman schizophrenia receive 60-120mg/d raloxifene compare placebo</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>1 . Post menopausal female : Post menopausal define : Women 45 year age old vaginal bleeding least 2 year prior randomization , serum estradiol &lt; 73 pmol/L ( 20 pg/mL ) FSH &gt; 30 IU/L ( 30 mIU/mL ) . 2 . 4565 year old 3 . Willing able provide inform consent , nature study fully explain . 4 . Current DSMIVTR diagnosis schizophrenia schizoaffective disorder confirm modified SCID least 2 prior schizophrenic episode , continually ill least 6 month . 5 . Symptoms : 4 ( moderate ) CGIS 4 ( moderate ) score two follow four PANSS item : delusion , hallucinatory behavior , conceptual disorganization suspiciousness/ persecution , and/or total PANSS negative symptom score 18 . 6 . Must antipsychotic drug , least 2 week prior baseline visit , dos within PORT criterion , whenever possible . Patients receive high dos record review insure dose require , possible , stabilize low dose prior study entry . 7 . Inpatients outpatient . Inpatients randomize 3 day admission . 1 . Unwilling unable , opinion Investigator , comply study instruction 2 . Women child bear potential . 3 . Women amenorrhea due cause natural surgical menopause i.e . eat disorder exercise 4 . Unstable medical disease ( malignancy , poorly control diabetes , active ischemic cardiac disease , cardiomyopathy , serious pulmonary disease , kidney disease , impair liver function . 5 . Patients treated cholestyramine , warfarin concurrent systemic estrogen therapy 6 . Likely allergy sensitivity raloxifene . 7 . At significant risk commit suicide , opinion Investigator , currently imminent risk suicide harm others . 8 . Patients current DSMIV substance alcohol abuse . Patients history and/or current recreational use cannabinoids alcohol , and/or patient smoke cigarette include . 9 . Concurrent delirium , mental retardation , druginduced psychosis , history brain trauma . 10 . Patients hypercoaguable condition risk venous thrombosis .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
</DOC>